IP Library Granted Patent US 9,233,095
Granted Patent B2
US 9,233,095 · App. 13/981,015 · Granted Jan 12, 2016

Small molecule RNase inhibitors and methods of use

Inventors: Paul M. Dunman (Pittsford, NY); Patrick D. Olson (St. Louis, MO); Wayne Childers (New Hope, PA)
Assignees: University of Rochester; Board of Regents of the University of Nebraska; Temple University—Of the Commonwealth System of Higher Education
A61K31/341C07D307/56C07D307/68A61K31/402A61K31/427A61K45/06C07D207/337C07D405/06C07D417/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,095
App. No.
13/981,015
Granted
Jan 12, 2016
Kind
B2
Abstract

Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection.

Claims (10)

1. A method of treating or preventing a microbial infection in a subject, comprising administering to the subject an effective amount of an RNase inhibitor of the following structure:

or a pharmaceutically acceptable salt or prodrug thereof.

2. The method of claim 1 , wherein the microbial infection is a bacterial infection.

3. The method of claim 2 , wherein the bacterial infection is a Gram positive bacterial infection.

4. The method of claim 2 , wherein the bacterial infection is a Staphylococcus infection.

5. The method of claim 2 , wherein the bacterial infection is a Staphylococcus aureus infection.

6. The method of claim 5 , wherein the Staphylococcus aureus infection is a drug-resistant Staphylococcus aureus infection.

7. The method of claim 5 , wherein the Staphylococcus aureus infection is a biofilm-associated Staphylococcus aureus infection.

8. The method of claim 1 , wherein the RNase inhibitor is an RnpA inhibitor.

9. The method of claim 1 , further comprising administering a second compound, wherein the second compound is an antibacterial compound.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 31, 2014
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034715/0722 →
CONFIRMATORY LICENSE Recorded Dec 12, 2014
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034627/0611 →
CONFIRMATORY LICENSE Recorded Jan 15, 2014
From: UNIVERSITY OF ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032021/0167 →
Continuity (2)
Provisional Application 61436342 · Jan 26, 2011
Related Publication 20130303585A1 · Nov 14, 2013